LORICRIN and neoplasm: In this respect, we have recently defined the combined loss of the autophagy regulatory protein autophagy‐and‐beclin‐1 regulator 1 (AMBRA1) and epidermal differentiation marker loricrin (AMLo) in the tumour microenvironment as a prognostic biomarker for early‐stage primary melanoma, associated with a significantly increased risk of metastasis.8